

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A61K 38/09, 47/00</b>		A1	(11) International Publication Number: <b>WO 98/08533</b> (43) International Publication Date: <b>5 March 1998 (05.03.98)</b>
<p>(1) International Application Number: <b>PCT/AU97/00560</b></p> <p>(22) International Filing Date: <b>1 September 1997 (01.09.97)</b></p> <p>(30) Priority Data: PO 2035 30 August 1996 (30.08.96) AU PO 4107 6 December 1996 (06.12.96) AU</p> <p>(71) Applicant (<i>for all designated States except US</i>): PEPTECH LIMITED [AU/AU]; 35-41 Waterloo Road, North Ryde, NSW 2113 (AU).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): TRIGG, Timothy, Elliot [AU/AU]; 8 Yosefa Avenue, Warrawee, NSW 2074 (AU). WALSH, John, Desmond [AU/AU]; 5 Stregess Avenue, Curl Curl, NSW 2096 (AU). SCHOBERT, Paul, Adam [AU/AU]; 34 Cousins Road, Beacon Hill, NSW 2100 (AU).</p> <p>(74) Agent: F.B. RICE &amp; CO.; 28A Montague Street, Balmain, NSW 2041 (AU).</p>			
<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>			

(54) Title: SUSTAINED PEPTIDE-RELEASE FORMULATION

(57) Abstract

A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15 % (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5 % (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.